Literature DB >> 27814993

Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study.

Lisa Wang1, Michael G Heckman2, Jan O Aasly3, Grazia Annesi4, Maria Bozi5, Sun Ju Chung6, Carl Clarke7, David Crosiers8, Gertrud Eckstein9, Gaetan Garraux10, Georgios M Hadjigeorgiou11, Nobu Hattori12, Beom Jeon13, Yun J Kim14, Masato Kubo15, Suzanne Lesage16, Juei Jueng Lin17, Timothy Lynch18, Peter Lichtner9, George D Mellick19, Vincent Mok20, Karin E Morrison21, Aldo Quattrone22, Wataru Satake23, Peter A Silburn24, Leonidas Stefanis25, Joanne D Stockton26, Eng King Tan27, Tatsushi Toda23, Alexis Brice16, Christine Van Broeckhoven28, Ryan J Uitti29, Karin Wirdefeldt30, Zbigniew Wszolek29, Georgia Xiromerisiou11, Demetrius M Maraganore31, Thomas Gasser32, Rejko Krüger33, Matthew J Farrer34, Owen A Ross35, Manu Sharma36.   

Abstract

A recent study MacLeod et al. has shown that an interaction between variants at the LRRK2 and PARK16 loci influences risk of development of Parkinson's disease (PD). Our study examines the proposed interaction between LRRK2 and PARK16 variants in modifying PD risk using a large multicenter series of PD patients (7715) and controls (8261) from sites participating in the Genetic Epidemiology of Parkinson's Disease Consortium. Our data does not support a strong direct interaction between LRRK2 and PARK16 variants; however, given the role of retromer and lysosomal pathways in PD, further studies are warranted.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetic epidemiology; LRRK2; PARK16; Parkinson's disease

Mesh：

Substances：

Year:  2016        PMID： 27814993      PMCID： PMC5154911          DOI： 10.1016/j.neurobiolaging.2016.09.022

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


  8 in total

1.  GWAS risk factors in Parkinson's disease: LRRK2 coding variation and genetic interaction with PARK16.

Authors:  Alexandra I Soto-Ortolaza; Michael G Heckman; Catherine Labbé; Daniel J Serie; Andreas Puschmann; Sruti Rayaprolu; Audrey Strongosky; Magdalena Boczarska-Jedynak; Grzegorz Opala; Anna Krygowska-Wajs; Maria Barcikowska; Krzysztof Czyzewski; Timothy Lynch; Ryan J Uitti; Zbigniew K Wszolek; Owen A Ross
Journal:  Am J Neurodegener Dis       Date:  2013-11-29

Review 2.  Advances in the genetics of Parkinson disease.

Authors:  Joanne Trinh; Matt Farrer
Journal:  Nat Rev Neurol       Date:  2013-07-16       Impact factor: 42.937

3.  Independent and joint effects of the MAPT and SNCA genes in Parkinson disease.

Authors:  Alexis Elbaz; Owen A Ross; John P A Ioannidis; Alexandra I Soto-Ortolaza; Frédéric Moisan; Jan Aasly; Grazia Annesi; Maria Bozi; Laura Brighina; Marie-Christine Chartier-Harlin; Alain Destée; Carlo Ferrarese; Alessandro Ferraris; J Mark Gibson; Suzana Gispert; Georgios M Hadjigeorgiou; Barbara Jasinska-Myga; Christine Klein; Rejko Krüger; Jean-Charles Lambert; Katja Lohmann; Simone van de Loo; Marie-Anne Loriot; Timothy Lynch; George D Mellick; Eugénie Mutez; Christer Nilsson; Grzegorz Opala; Andreas Puschmann; Aldo Quattrone; Manu Sharma; Peter A Silburn; Leonidas Stefanis; Ryan J Uitti; Enza Maria Valente; Carles Vilariño-Güell; Karin Wirdefeldt; Zbigniew K Wszolek; Georgia Xiromerisiou; Demetrius M Maraganore; Matthew J Farrer
Journal:  Ann Neurol       Date:  2011-03-09       Impact factor: 10.422

Review 4.  Parkinson's disease: from monogenic forms to genetic susceptibility factors.

Authors:  Suzanne Lesage; Alexis Brice
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

5.  Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.

Authors:  Michael G Heckman; Alexis Elbaz; Alexandra I Soto-Ortolaza; Daniel J Serie; Jan O Aasly; Grazia Annesi; Georg Auburger; Justin A Bacon; Magdalena Boczarska-Jedynak; Maria Bozi; Laura Brighina; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Alain Destée; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; Suzana Gispert; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Chin-Hsien Lin; Katja Lohmann; Marie-Anne Loriot; Timothy Lynch; George D Mellick; Eugénie Mutez; Grzegorz Opala; Sung Sup Park; Simona Petrucci; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Georgia Xiromerisiou; Demetrius M Maraganore; Matthew J Farrer; Owen A Ross
Journal:  Neurobiol Aging       Date:  2013-08-17       Impact factor: 4.673

6.  RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk.

Authors:  David A MacLeod; Herve Rhinn; Tomoki Kuwahara; Ari Zolin; Gilbert Di Paolo; Brian D McCabe; Brian D MacCabe; Karen S Marder; Lawrence S Honig; Lorraine N Clark; Scott A Small; Asa Abeliovich
Journal:  Neuron       Date:  2013-02-06       Impact factor: 17.173

7.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.

Authors:  Michael A Nalls; Vincent Plagnol; Dena G Hernandez; Manu Sharma; Una-Marie Sheerin; Mohamad Saad; J Simón-Sánchez; Claudia Schulte; Suzanne Lesage; Sigurlaug Sveinbjörnsdóttir; Kári Stefánsson; Maria Martinez; John Hardy; Peter Heutink; Alexis Brice; Thomas Gasser; Andrew B Singleton; Nicholas W Wood
Journal:  Lancet       Date:  2011-02-01       Impact factor: 79.321

8.  Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.

Authors:  Alexandria Beilina; Iakov N Rudenko; Alice Kaganovich; Laura Civiero; Hien Chau; Suneil K Kalia; Lorraine V Kalia; Evy Lobbestael; Ruth Chia; Kelechi Ndukwe; Jinhui Ding; Mike A Nalls; Maciej Olszewski; David N Hauser; Ravindran Kumaran; Andres M Lozano; Veerle Baekelandt; Lois E Greene; Jean-Marc Taymans; Elisa Greggio; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-07       Impact factor: 11.205
  8 in total
  1 in total

1.  Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.

Authors:  Kenneth Thirstrup; Justus C Dächsel; Felix S Oppermann; Douglas S Williamson; Garrick P Smith; Karina Fog; Kenneth V Christensen
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.